Theseus Pharmaceuticals is passionately committed to outsmarting cancer resistance. Cancer is constantly mutating, allowing it to evade initially effective oncology treatments. Theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. Led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (TKIs), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.
Employees: 11-50
Total raised: $100M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 04.05.2021 | Omega Fund... | omegafunds... |
| - | OrbiMed | orbimed.co... |
| 28.04.2021 | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.04.2021 | Series B | $100M | Foresite C... |
Mentions in press and media 12
| Date | Title | Description |
| 14.11.2023 | Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the latest twist in the Ozempic panic, polarizing data in genome editing, and anot... |
| 02.02.2022 | Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) | CAMBRIDGE, Mass., Feb. 2, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and comme... |
| 10.01.2022 | Theseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) | CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and comm... |
| 15.11.2021 | Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results | CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transfor... |
| 01.11.2021 | Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GI... | CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ --Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of tra... |
| 04.05.2021 | Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer | |
| 13.04.2021 | Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors | - |
| 13.04.2021 | Theseus Pharmaceuticals Emerges With $100M | BOSTON, MA, Theseus Pharmaceuticals emerged from stealth today announcing the close of a $100 million Series B financing. >> Click here for more funding data on Theseus Pharmaceuticals >> To export Theseus Pharmaceuticals fu... |
| 13.04.2021 | Theseus Pharmaceuticals Raises $100M in Series B Funding | Theseus Pharmaceuticals, a Boston, MA-based biotechnology company focused on oncology by developing pan-variant kinase inhibitors, emerged from stealth with the close of a $100m Series B financing. The round was led by Foresite Capital with... |
| 13.04.2021 | Theseus Pharmaceuticals, Inc. announced that it has received $100 million in funding from a group of investors | On April 13, 2021, Theseus Pharmaceuticals, Inc. closed the transaction. The company has raised $100,000,000 in the transaction. The transaction was led by new investor Foresite Capital Management, LLC, and involved participation from new i... |
Show more